A 48-year-old man with a 6-month history of recurrent epigastric pain and dyspepsia undergoes upper endoscopy. Gastric biopsy reveals chronic active gastritis with intestinal metaplasia. Rapid urease test is positive. What is the drug of choice as part of the first-line eradication regimen for this condition?

Explanation

## Helicobacter pylori Eradication: First-Line Regimen ### Diagnosis Confirmation **Key Point:** The positive rapid urease test on gastric biopsy confirms *Helicobacter pylori* infection. Chronic active gastritis with intestinal metaplasia indicates long-standing infection and increased risk of gastric cancer and peptic ulcer disease. ### First-Line Eradication Therapy: Triple Therapy **High-Yield:** The gold-standard first-line regimen is **proton pump inhibitor (PPI) + clarithromycin + amoxicillin** (or metronidazole if penicillin-allergic). Clarithromycin is a cornerstone macrolide antibiotic in this combination. ### Standard Triple Therapy Regimen | Component | Drug | Dose | Duration | |-----------|------|------|----------| | **PPI** | Omeprazole (or lansoprazole, pantoprazole) | 20–40 mg BD | 7–14 days | | **Macrolide** | **Clarithromycin** | 500 mg BD | 7–14 days | | **Beta-lactam** | Amoxicillin | 1 g BD | 7–14 days | | **Alternative** | Metronidazole (if PCN-allergic) | 400–500 mg BD | 7–14 days | **Clinical Pearl:** Clarithromycin is preferred over erythromycin or azithromycin in triple therapy because it has superior eradication rates (~90%) when combined with a PPI and amoxicillin. It achieves high intracellular concentrations in gastric mucosa and is bactericidal against *H. pylori*. ### Why Clarithromycin is Essential 1. **Mechanism:** 50S ribosomal inhibition; bactericidal activity 2. **Gastric penetration:** Excellent mucosal and intracellular concentration 3. **Eradication rates:** ~90% with triple therapy (PPI + clarithromycin + amoxicillin) 4. **Evidence base:** Guideline-recommended as first-line macrolide in multiple international guidelines (ACG, ASGE, Maastricht V) ### Alternative Regimens (if clarithromycin resistance or allergy) **Mnemonic:** **MALT** (Metronidazole, Amoxicillin, Levofloxacin, Tinidazole) — alternative agents when clarithromycin cannot be used. - **Quadruple therapy (bismuth-based):** PPI + bismuth subsalicylate + metronidazole + tetracycline (7–14 days) - **Sequential therapy:** PPI + amoxicillin (5 days), then PPI + clarithromycin + tinidazole (5 days) - **Levofloxacin-based:** PPI + amoxicillin + levofloxacin (for clarithromycin-resistant strains) **Warning:** Clarithromycin resistance is increasing globally (15–40% in some regions) and is the primary driver of triple-therapy failure. If resistance is suspected or eradication fails, switch to quadruple or sequential therapy. ### Post-Eradication Confirmation - **Test of cure:** Perform 4 weeks after completing therapy using urea breath test, stool antigen test, or repeat endoscopy with biopsy - **Proton pump inhibitor timing:** Stop PPI 2 weeks before testing (may cause false negatives) [cite:Harrison 21e Ch 160; Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 9e]